Amsterdam, The Netherlands and San Antonio, TX, USA, July 13, 2009 – International publisher IOS Press and the Editors-in-Chief of the Journal of Alzheimer's Disease (JAD) are pleased to announce that once again there has been a significant increase in the Journal's Impact Factor, from 4.081 to 5.101 for 2008 according to Thomson Reuters' Journal Citation Reports 2009. The Journal of Alzheimer's Disease continues to strengthen and build on its lead as the most prolific and highly cited journal in the Alzheimer's disease (AD) field. With an Impact Factor of over 5, JAD is now on par with or exceeds the ranking of some of the most established and highly regarded journals in the neurosciences, pathology and biochemistry.
Editors-in-Chief George Perry and Mark A. Smith commented, "As we celebrate JAD's 10th anniversary this year, it is extremely rewarding to see tangible evidence of the Journal's continually increasing value to AD researchers and academic physicians. Our primary goal is to promote the understanding of AD by building on the discoveries of the past, advancing research to identify preventive methods and improve treatment and working towards finding a cure. The dedication of the entire editorial board, contributing authors and our publisher, IOS Press, has been the key to the Journal's success."
"The Journal of Alzheimer's Disease is one of our flagship publications," stated Einar Fredriksson, Director of IOS Press. "It is extremely gratifying to see the impact that this journal is having in the field. As a specialist journal, it is particularly significant that it is ranked among the top journals included in JCR's Neurosciences category."
The Journal of Alzheimer's Disease (www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes.
About IOS Press
For over twenty years IOS Press (www.iospress.nl) has been servicing a variety of scientific and medical communities worldwide. Commencing its publishing activities in 1987, IOS Press now publishes about 150 book titles each year, with subjects ranging from computer sciences and mathematics to medicine and the natural sciences. We also publish some 90 international journals on a number of subjects. IOS Press is a rapidly-growing publishing company that embraces new technologies for the dissemination of information. All journals are available online and an online book platform was launched in the first half of 2006. Following its founding, IOS Press established several co-publishing initiatives. Its most recent expansion is the acquisition of Delft University Press at the end of 2005. IOS Press also maintains offices in the Washington, DC area, Berlin and a co-publishing relationship with Ohmsha, Ltd (Tokyo).